NCT04727138View on ClinicalTrials.gov

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

April 16, 2022

Study Completion Date

May 12, 2022

Conditions
Oncology
Interventions
DRUG

EXS21546 Powder for Oral Suspension

EXS21546 Powder for Oral Suspension

DRUG

EXS21546 Granule in Capsule

EXS21546 Granule in Capsule

OTHER

Midazolam

Interaction

OTHER

Food Effect

Fed/Fasted

OTHER

Placebo Powder for Oral Suspension

Placebo Powder for Oral Suspension

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Exscientia AI Limited

INDUSTRY

NCT04727138 - 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 | Biotech Hunter | Biotech Hunter